135 related articles for article (PubMed ID: 18315555)
21. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
22. Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements.
Mayeda A; Screaton GR; Chandler SD; Fu XD; Krainer AR
Mol Cell Biol; 1999 Mar; 19(3):1853-63. PubMed ID: 10022872
[TBL] [Abstract][Full Text] [Related]
23. ESEfinder: A web resource to identify exonic splicing enhancers.
Cartegni L; Wang J; Zhu Z; Zhang MQ; Krainer AR
Nucleic Acids Res; 2003 Jul; 31(13):3568-71. PubMed ID: 12824367
[TBL] [Abstract][Full Text] [Related]
24. hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B.
Expert-Bezançon A; Sureau A; Durosay P; Salesse R; Groeneveld H; Lecaer JP; Marie J
J Biol Chem; 2004 Sep; 279(37):38249-59. PubMed ID: 15208309
[TBL] [Abstract][Full Text] [Related]
25. Two members of a conserved family of nuclear phosphoproteins are involved in pre-mRNA splicing.
Mayeda A; Zahler AM; Krainer AR; Roth MB
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1301-4. PubMed ID: 1741384
[TBL] [Abstract][Full Text] [Related]
26. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells.
Shih SR; Krug RM
EMBO J; 1996 Oct; 15(19):5415-27. PubMed ID: 8895585
[TBL] [Abstract][Full Text] [Related]
27. PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer.
Wang E; Huang Z; Hobson GM; Dimova N; Sperle K; McCullough A; Cambi F
J Cell Biochem; 2006 Apr; 97(5):999-1016. PubMed ID: 16288477
[TBL] [Abstract][Full Text] [Related]
28. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.
Mercado PA; Ayala YM; Romano M; Buratti E; Baralle FE
Nucleic Acids Res; 2005; 33(18):6000-10. PubMed ID: 16254078
[TBL] [Abstract][Full Text] [Related]
29. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions.
Liu HX; Chew SL; Cartegni L; Zhang MQ; Krainer AR
Mol Cell Biol; 2000 Feb; 20(3):1063-71. PubMed ID: 10629063
[TBL] [Abstract][Full Text] [Related]
30. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors.
Hanamura A; Cáceres JF; Mayeda A; Franza BR; Krainer AR
RNA; 1998 Apr; 4(4):430-44. PubMed ID: 9630249
[TBL] [Abstract][Full Text] [Related]
31. Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs.
Belshan M; Park GS; Bilodeau P; Stoltzfus CM; Carpenter S
Mol Cell Biol; 2000 May; 20(10):3550-7. PubMed ID: 10779344
[TBL] [Abstract][Full Text] [Related]
32. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing.
Kashima T; Rao N; David CJ; Manley JL
Hum Mol Genet; 2007 Dec; 16(24):3149-59. PubMed ID: 17884807
[TBL] [Abstract][Full Text] [Related]
33. Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins.
Lemaire R; Prasad J; Kashima T; Gustafson J; Manley JL; Lafyatis R
Genes Dev; 2002 Mar; 16(5):594-607. PubMed ID: 11877379
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the SR proteins ASF/SF2 and SC35 influences alternative splicing in vivo in diverse ways.
Wang J; Manley JL
RNA; 1995 May; 1(3):335-46. PubMed ID: 7489505
[TBL] [Abstract][Full Text] [Related]
35. Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.
Carter JG; Cherry J; Williams K; Turner S; Bates DO; Churchill AJ
Curr Eye Res; 2011 Apr; 36(4):328-35. PubMed ID: 21309690
[TBL] [Abstract][Full Text] [Related]
36. The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20.
Galiana-Arnoux D; Lejeune F; Gesnel MC; Stevenin J; Breathnach R; Del Gatto-Konczak F
J Biol Chem; 2003 Aug; 278(35):32943-53. PubMed ID: 12826680
[TBL] [Abstract][Full Text] [Related]
37. Identification of nuclear and cytoplasmic mRNA targets for the shuttling protein SF2/ASF.
Sanford JR; Coutinho P; Hackett JA; Wang X; Ranahan W; Caceres JF
PLoS One; 2008 Oct; 3(10):e3369. PubMed ID: 18841201
[TBL] [Abstract][Full Text] [Related]
38. Genetic analysis of the SR protein ASF/SF2: interchangeability of RS domains and negative control of splicing.
Wang J; Xiao SH; Manley JL
Genes Dev; 1998 Jul; 12(14):2222-33. PubMed ID: 9679066
[TBL] [Abstract][Full Text] [Related]
39. Subtle discrepancies of SF2/ASF ESE sequence motif among human tissues: A computational approach.
Siala O; Rebai A; Baklouti F; Fakhfakh F
Comput Biol Chem; 2010 Jun; 34(3):203-9. PubMed ID: 20637698
[TBL] [Abstract][Full Text] [Related]
40. The deep intronic c.903+469T>C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria.
Homolova K; Zavadakova P; Doktor TK; Schroeder LD; Kozich V; Andresen BS
Hum Mutat; 2010 Apr; 31(4):437-44. PubMed ID: 20120036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
